Company Overview of Ability Biomedical Corp.
Ability Biomedical Corporation develops chemokine-based therapeutics for treatment of Multiple Sclerosis (MS), as well as acute spinal cord and brain injuries. The company is researching the efficacy of injectable interferon-inducible protein 10 (IP-10) antibody in alleviating and improving symptoms of multiple sclerosis, and eliminating physical deterioration post-spinal cord injury. Ability Biomedical was founded in 2002 and is based in Vancouver, Canada. As of August 2004, Ability Biomedical Corporation was a subsidiary of Medarex Inc. Later, it operates as a subsidiary of Bristol-Myers Squibb Company.
1055 West Georgia Street
Vancouver, BC V6E 3R5
Founded in 2002
Key Executives for Ability Biomedical Corp.
Similar Private Companies By Industry
|Drake International Inc.||Americas|
|The Verriez Group Inc.||Americas|
|ALS Chemex Labs, Ltd.||Americas|
|Colas Moreira Kazandjian Zikovsky, LLP||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Ability Biomedical Corp., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.